PharmNXT Biotech unveils maiden integrated manufacturing unit for single-use bioprocessing systems

In line with ‘Make in India,’ Mumbai-based PharmNXT Biotech yesterday launched its first integrated manufacturing unit to provide single-use bioprocessing solutions. The state-of-the-art facility has been launched to address the challenges of biologics manufacturing in the country. The manufacturing unit, spread over 40,000 sq ft, will be called PharmNXT ekuse, a statement from PharmNXT Biotech informed.

The statement said that the new facility was launched at the company’s facility in Chakan, Pune, in the presence of experts from the Indian biopharma fraternity. The event began with the keynote address by Dr Dhananjay Patankar, thought leader in the biopharma industry on the aspect of single-use technologies within biopharma space and how manufacturing these technologies in India is crucial to address the supply dependencies on foreign suppliers.

Housing the latest production technology, the plant is built to provide single-use bioprocessing solutions “made in India,” with plans to cater to the demands from global markets such as Singapore, Korea, Europe and the US. The new facility will also generate employment opportunities to more than 100 to 200 people. The ekuse manufacturing facility will be engaged in crafting the Xelta range of single-use bioprocessing products and ‘NXTmix’ a levitating mixing technology, as per the statement.

“With the launch of this unit, we have stepped up our efforts to empower our regional and global clients and provide single-use products, solutions at an accelerated pace. It is our vision to understand customer needs and provide solutions that bring efficiency and consistency in their manufacturing. This new site will support the government’s ‘Make in India’ vision to find solutions for the evolving needs for high-quality single-use biopharmaceutical products. We are going to manufacture single-use technologies like single-use storage bags and single-use mixing solutions from this site,” said Sachin Joshi, founder, PharmNXT Biotech, in the statement.

Further, according to the statement, Dr Patankar said that this is the great beginning towards self-sustenance of the critical raw material that is needed for biopharma manufacturing.

Adding to it, Sandeep Raktate, Senior VP, Cipla, also said in the statement, “………..The localisation of the single-use solution will ease the bottleneck of the supply chain to bring in the consistency and accelerate the overall biopharma eco-system.”